Translational research has always been the linchpin of Lifedoc’s clinical framework, further enabling us to provide healthcare that is quality-oriented and data-driven. Over the last 15 years, research has remained an integral part of our efforts to maximize the applicability of health data. With active participation in industry-sponsored and investigator-initiated research, we aim to to inform emerging treatments and continually refine our clinical model for the ultimate benefit of the patient. This focus allows us to continually develop data to support our evidence-based approach, ensuring that our patients receive the most effective healthcare and clinical interventions. Ultimately, this allows us to fulfill our mission of establishing Lifedoc as a reference model for researchers and practitioners studying the development and prevention of cardiometabolic conditions.
Take a look at our past and ongoing trials, research partnerships as well as some of our published/presented studies below.
Interested in working with our research site? Contact us.
Research Partnerships
Industry-sponsored Clinical Trials
Ongoing Trials
-
Abbvie
-
A Phase 2/3 Multicenter, Double-Blinded, Randomized, Dose-Conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults with Primary Hypothyroidism (Protocol: M21-341)
-
-
AstraZeneca AB
-
A Phase 3, Randomised, Double-Blind Study to Assess the Efficacy, Safety, and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants with CKD and High Blood Pressure (Baxduo) (Protocol: D6972C00003)
-
-
Bayer
-
A Non-Interventional Study Providing Insights into the Use of Finerenone in a Routine Clinical Setting (Fine-Real) (Protocol: 21785)
-
-
Eli Lilly
-
A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared with Placebo in Adult Participants with Type 2 Diabetes and Inadequate Glycemic Control with Diet and Exercise Alone (TRANSCEND-T2D-1) (Protocol: J1I-MC-GZBY)
-
-
Mineralys Therapeutics
-
An Open-Label Extension Study to Assess the Long-term Safety, Efficacy, and Tolerabiliyt of Lorundrostat in Subjects with Hypertension (Transform-HTN) (Protocol: MLS-101-901)
-
-
Novo Nordisk
-
Efficacy, Safety, and Pharmacokinetics of Cagrilintide S.C. 2.4 mg in Combination with Semaglutide S.C. 2.4 mg (CagriSema) Once Weekly for Weight Management in Children and Adolescents with Overweight or Obesity (Re-Define Young) (Protocol: NN9838-4968)
-
A Clinical Study of CagriSema on Maintaining Weight Reduction in Participants with Obesity (Protocol: NN9838-7909)
-
Efficacy and Safety of Co-Administered Cagrilintide and Semaglutide (CagriSema)
S.C. Once Weekly Versus Placebo in Children and Adolescents with Type 2 Diabetes (Re-Imagine Young) (Protocol: NN9388-7988)
-
Past Trials
– Janssen – Safety and Efficacy of SGLT-2 in Type 2 Diabetes, Adults – Recognized as Highest Recruiting/Retaining Site in the US
– Novo Nordisk – Safety and Efficacy of Liraglutide in Overweight and Obesity, Children and Adolescents 10-17 years of age – Recruited First and Second Patient Globally
– Novo Nordisk – Safety and Efficacy of Liraglutide and Metformin in Type 2 Diabetes, Children and Adolescents 10-17 years of age – Recognized as Highest Recruiting Site in the US
– Boehringer-Ingleheim – Safety and Efficacy of SGLT-2 and DPP-4 in Type 2 Diabetes, Children 10 – 17 years of age.
